经输液泵输入缩宫素引产初始滴速设置的研究

目的合理设置经输液泵输入缩宫素引产的初始滴速,为临床安全有效地输入缩宫素提供参考。方法将80例孕妇随机分为A组(24例)、B组(28例)与C组(28例),使用输液泵输入0.5%缩宫素液,三组分别以1、2、3 gtt/m in为初始滴速,此后根据宫缩每15分钟调整1次滴速,观察出现规律宫缩时所用的时间和滴速。结果静脉输注缩宫素后15 m in内A、B组无1例出现规律宫缩,C组有2例出现规律宫缩。22.5%孕妇在滴速续加至3~7 gtt/m in时出现规律宫缩。三组出现规律宫缩所用时间比较,差异有显著性意义(P<0.01),其中C组所用时间显著短于A、B组(P<0.01,P<0.05),B组显著短于A组(P<0.01)。结论从安全和时效的角度考虑,使用输液泵输注0.5%缩宫素初始滴速以3 gtt/m in(12 m l/h)为宜。     

输液泵滴注缩宫素引产效果观察

随机将460例需引产的孕妇分为两组各230例.观察组采用输液泵调节缩宫素引产,对照组常规用人工调节滴数.结果引产安全率、成功率观察组均高于对照组,差异有显著性意义(P＜0.05,P＜0.01);引产至临产时间观察组短于对照组(P＜0.05).总产程时间及产后出血量两组差异无显著性意义(均P＞0.05).提示引产中使用输液泵调节缩宫素滴数,可保持缩宫素有效血药浓度,维持规律宫缩,可避免强直性宫缩及胎儿宫内窘迫的发生,提高引产的安全性及成功率,缩短引产时间.     

1例胎死宫内孕妇缩宫素引产致过敏性休克的抢救护理

缩宫素是妇产科常用药物,临床上用于引产、催产、产后以及流产后因宫缩乏力或缩复不良而引起子宫出血,其不良反应较少。我科2010年8月收治1例孕妇,因胎死宫内静脉滴注缩宫素引产,输液过程中发生过敏性休克,经积极抢救及护理,患者痊愈出院。1病例简介女,29岁。于2010年8月12日14:00因"孕41+3周、胎     

Foley导尿管球囊联合缩宫素对孕妇促宫颈成熟引产效果的回顾性分析

目的 对宫颈评分小于等于6分的计划分娩孕妇,评估Foley导尿管球囊联合缩宫素对促进其子宫颈成熟引产效果,了解该方案的安全性。方法 本文采用回顾性方法分析2021年1月至2022年10月在阿克苏地区拜城县人民医院产科计划分娩的孕妇100例,根据治疗情况分为缩宫素组及联合组,各50例。缩宫素组应用缩宫素静滴引产,联合组应用Foley导尿管联合缩宫素静滴引产,收集患者一般资料,产程时间,剖宫产率、产后出血量,新生儿体重,新生儿Apgar评分,产后感染发生率,收集数据,并对数据进行比较分析,比较两组的引产效果。结果 两组孕妇年龄、学历、民族、孕前BMI、产时BMI（分娩前）,怀孕次数（孕次）,入院时血压、血红蛋白水平,其差异无统计学意义（P>0.05）;两组孕妇分娩后,新生儿体重,新生儿Apgar评分（1分钟,5分钟）进行比较,差异无统计学意义（P>0.05）。两组孕妇入院后评估宫颈Bishop评分,联合组子宫颈Bishop评分平均3.62分,缩宫素组子宫颈Bishop评分平均5.26分,差异有统计学意义（P<0.05）。通过对两组孕妇分娩结局的比较,联合组孕妇成功完成顺产...     

缩宫素对子宫肌瘤患者血流动力学的影响

缩宫素可以使子宫收缩而减少子宫出血。其作用的强度与人体内雌激素的水平相关。子宫肌瘤患者体内雌激素水平高于正常人，临床上在子宫肌瘤剔除术中常使用缩宫素来减少术中出血。本研究连续监测子宫肌瘤剔除术中使用缩宫素前后血流动力学的变化，以了解缩宫素对子宫肌瘤病人血流动力学的影响。     

欣普贝生、缩宫素在足月单胎妊娠引产促宫颈成熟临床效果观察

目的探讨欣普贝生、缩宫素分别在足月单胎妊娠引产促宫颈成熟的临床效果。方法将100例住院分娩的足月单胎妊娠分娩孕妇做为试验组;将100例同样条件的初产妇作为对照组,分别应用欣普贝生和缩宫素促宫颈成熟,观察两组临床效果。结果试验组用于足月单胎妊娠引产促宫颈成熟优效果于对照组。两组差异有统计学意义(P0.05)。结论欣普贝生用于足月单胎妊娠引产促宫颈成熟的临床效果明显优于缩宫素组,且产程明显缩短,不仅提高自然分娩率,而且降低了剖宫产率。     

超声造影评估缩宫素辅助对于高强度聚焦超声消融子宫肌瘤效果的影响

目的 通过超声造影(CEUS)观察缩宫素对高强度聚焦超声(HIFU)消融子宫肌瘤效果的影响。方法 回顾性分析48例接受缩宫素辅助HIFU治疗的子宫肌瘤患者。消融前对子宫肌瘤行首次CEUS;之后10 min以微量泵静脉泵入0.12 U/ml缩宫素20 min(1 ml/min),再次行CEUS,而后进行HIFU消融。根据泵入缩宫素后CEUS所示子宫肌瘤增强模式将患者分为无灌注组、部分灌注组及完全灌注组;对比3组消融参数、肌瘤消融率及满意消融率。结果 无灌注组13例,部分灌注组27例,完全灌注组8例。3组HIFU消融参数及消融率总体差异均有统计学意义(P均<0.05)。无灌注组辐照时间、治疗时间、治疗能量及能效因子(EEF)均小于部分灌注组及完全灌注组,部分灌注组上述参数均小于完全灌注组(P均<0.05);无灌注组消融率及满意消融率大于部分灌注组及完全灌注组,部分灌注组上述参数大于完全灌注组(P均<0.05)。结论 以缩宫素辅助可提高HIFU消融子宫肌瘤效果;但在部分对缩宫素不敏感患者难以实现增效作用。     

缩宫素联合米索前列醇治疗产后出血的临床效果研究

目的 探讨缩宫素联合米索前列醇治疗产后出血(PPH)的临床效果.方法 回顾性分析2018-06-2020-06间新安县人民医院收治的86例产后出血患者,根据用药方法分为2组,各43例.对照组给予缩宫素治疗,观察组应用缩宫素联合米索前列醇治疗.比较2组患者的一般资料、止血效果、止血时间、住院时间、出血量及并发症.结果 2...     

垂体后叶素或缩宫素在腹腔镜肌壁间子宫肌瘤剔除术中应用的对比研究

目的探讨腹腔镜肌壁间子宫肌瘤剔除术应用垂体后叶素及缩宫素止血的优缺点。方法 2008年1月-2009年6月对68例肌壁间子宫肌瘤施行腹腔镜子宫肌瘤剔除术;32例为垂体后叶素组,切开浆膜层前子宫肌层注射垂体后叶素6 IU＋0.9%氯化钠注射液10 ml;36例为缩宫素组,注射缩宫素20 IU＋0.9%氯化钠注射液10 ml。比较2组手术时间、术中出血量、术后血红蛋白及用药前后血压的变化。结果 2组手术均顺利完成,无中转开腹。垂体后叶素组及缩宫素组相比,手术时间明显减少[（69.8±18.0）min vs.（82.8±17.6）min,t=-3.008,P=0.004],术中出血量明显减少[（68.5±19.6）ml vs.（88.5±25.6）ml,t=-3.583,P=0.000],术后血红蛋白下降幅度小[（11.0±2.6）g/L vs.（12.5±2.9）g/L,t=-2.234,P=0.029]。术中用药后15 min,垂体后叶素组收缩压上升,显著高于缩宫素组[（152.0±8.5）mm Hg vs.（146.5±10.2）mm Hg,t=2.398,P=0.019],用药30 min和45 min后,垂体后叶素组与缩宫素组收缩压无显著性差异（P〉0.05）。结论腹腔镜肌壁间子宫肌瘤切除术中使用垂体后叶素止血效果优于缩宫素,可明显减少术中出血,减少手术时间,值得推广应用。     

腹腔镜子宫肌瘤切除术中垂体后叶素及缩宫素止血作用的对比研究

目的:探讨腹腔镜子宫肌瘤切除术中用垂体后叶素及缩宫素止血的优缺点。方法:回顾分析我院2007年1月至12月用腹腔镜为52例子宫肌瘤患者行子宫肌瘤切除术的临床资料,26例为垂体后叶素组,于切开浆膜层前子宫肌层注射垂体后叶素10μ;26例为缩宫素组,注射缩宫素10μ。分析手术时间、术中出血量及术后血红蛋白的变化。结果:平均手术时间缩宫素组为(115.30±62.50)min,明显长于垂体后叶素组的(95.60±52.80)min(P<0.05),术中出血量垂体后叶素组(70.20±34.60)ml,明显少于缩宫素组的(160.20±52.50)ml(P<0.05);术后血红蛋白下降值垂体后叶素组为(8.22±1.17)g/L,明显低于缩宫素组的(12.10±3.42)g/L(P<0.05)。结论:腹腔镜子宫肌瘤切除术中使用垂体后叶素止血效果优于缩宫素,是一种有效的止血方法。     

间苯三酚联合缩宫素静滴促宫颈成熟及产程进展的临床疗效分析

目的探讨间苯三酚联合缩宫素静滴促宫颈成熟及产程进展的临床疗效。方法选择足月妊娠单胎头位104例需引产初产妇,采用单盲法随机分为两组各52例。研究组予间苯三酚120 mg加入5%葡萄糖250 ml静脉滴注,继而缩宫素2.5 U加入5%葡萄糖500 ml静脉滴注;对照组单纯予缩宫素2.5 U加入5%葡萄糖500 ml静脉滴注。记录并比较两组宫颈成熟度、产程进展、阴道分娩率、新生儿Apgar评分、产后阴道出血量及用药后母婴不良反应。结果研究组宫颈成熟度Bishop评分改善程度明显优于对照组,总产程时间明显短于对照组,阴道分娩率明显高于对照组,差异均有统计学意义(P0.05)。两组产后阴道出血量、新生儿Apgar评分比较差异均无统计学意义(P0.05),用药后母婴均无明显不良反应出现。结论间苯三酚联合缩宫素能促进宫颈成熟,加速产程进展,提高阴道分娩率,且对母婴无不良影响。     

Use of a Regional Infusion Pump to Control Postoperative Pain After an Abdominoplasty

This study presents the clinical results for 20 patients who underwent abdominoplasty. A subset of these patients were given a pain relief system that provides continuous infusion of a nonnarcotic medication directly into the surgical wound to reduce postoperative pain. Whereas patients received a pain pump in addition to standard oral/intramuscular pain medication, 10 patients received only the standard oral and intramuscular postoperative pain medications. All 20 patients then were asked to complete an evaluation of their postoperative discomfort and pain. The findings show a significant reduction in postoperative pain with the use of the ambulatory pain pump. The simplicity of installing and running the pump and the benefits obtained, including early ambulation and less pain as well as reduced need and strength of narcotic medications lead the authors to believe that the implementation of this pain control technology soon will become widespread in their specialty. The study indicates that patients require less sedation and get out of bed sooner with this device, thereby reducing the incidence of deep venous thrombosis, pulmonary emboli, and narcoticdependency. Presented at the annual meeting of the ASAPS (American Society of Aesthetic Plastic Surgery) and ASERF, The Aesthetic Meeting 2004, Vancouver, BC, April, 2004, and The Annual Meeting of the American Society of Plastic Surgeons, Philadelphia, PA, USA 9–13 October 2004. Dr. Mentz is a clinical assistant professor in the Department of Plastic Surgery at Baylor College of Medicine in Houston, TX, Dr. Ruiz-Razura is a professor in the Division of Plastic & Reconstructive Surgery at the University of Texas Medical School, Health Science Center in Houston.     

晚期妊娠引产临床观察

目的 比较米索前列醇（简称米索）、催产素、小剂量米索＋催广素用于晚期妊娠引产的效果。方法 100例孕37～42周的单胎头位产妇，均具有引产指征，随机分为A组（28例）、B组（35例）及C组（37例），分别给予阴道后穹舒降置入米索、静滴催产素以及小剂量米索加催加素引产，比较三组宫颈评分、总产程、分娩方式、出血量、新生儿Apgar计分、药物副反应差异。结果 C组分别与A、B组比较，平均引产成功率高，而平均总产程短、胎儿窘迫率、剖宫产率低（P〈0．05），出血量、新生儿Apgar评分比较无显著差异（P〉0．05）。结论 小剂量米索＋催产素用于晚期妊娠引产安全有效。     

小剂量米索前列醇应用于足月妊娠引产50例临床分析

目的 探讨小剂量米索前列醇在足月妊娠引产中的有效性和安全性. 方法 选择有引产指征的单胎足月妊娠初产妇100例,随机分为2组:米索前列醇组50例,予25μg米索前列醇置于阴道后穹窿,6h无临产可重复同剂量用药,24 h内总量不超过50 μg;缩宫素组50例,予常规5 U/L缩宫素静滴. 结果 米索前列醇组引产有效率高于缩宫素组(96％ vs.76％,P＜0.01),且最后一次用药至临产时间为(5.48±2.44)h、分娩总产程时间为(5.59±2.56)h,分别短于缩宫素组的(8.26±6.75)h和(8.65 ±7.34)h(P ＜0.05),剖宫产率低于缩宫素组(4％ vs.36％,P＜0.01),急产率高于缩宫素组(22％ vs.2％,P＜0.01);而产后出血率、新生儿窒息率两组比较均无统计学差异(P＞0.05).结论 小剂量米索前列醇用于足月妊娠引产安全、经济、有效、方便,更值得在基层医院临床推广.     

Single‐Dose Volume Regulation Algorithm for a Gas‐Compensated Intrathecal Infusion Pump

The internal pressures of medication reservoirs of gas‐compensated intrathecal medication infusion pumps decrease when medication is discharged, and these discharge‐induced pressure drops can decrease the volume of medication discharged. To prevent these reductions, the volumes discharged must be adjusted to maintain the required dosage levels. In this study, the authors developed an automatic control algorithm for an intrathecal infusion pump developed by the Korean National Cancer Center that regulates single‐dose volumes. The proposed algorithm estimates the amount of medication remaining and adjusts control parameters automatically to maintain single‐dose volumes at predetermined levels. Experimental results demonstrated that the proposed algorithm can regulate mean single‐dose volumes with a variation of <3% and estimate the remaining medication volume with an accuracy of >98%.     

Effective Treatment of Single-Stage Revision Using Intra-Articular Antibiotic Infusion for Polymicrobial Periprosthetic Joint Infection

BackgroundThe treatment of polymicrobial periprosthetic joint infection (PJI) confronted distinct challenges. No reports have assessed the efficacy of local antibiotic delivery combined with 1-stage exchange in polymicrobial PJI.MethodsBetween January 2013 and December 2018, we retrospectively analyzed the data of 126 patients, including 19 polymicrobial PJIs and 107 monomicrobial PJIs, who underwent single-stage revision using intra-articular antibiotic infusion. The risk factors, microbiology, infection control rate, and clinical outcomes were compared between the 2 groups.ResultsHigher body mass index, presence of a sinus tract, and prior revisions were the risk factors for polymicrobial PJI. Isolation of Staphylococcus epidermidis, Streptococcus, Enterococcus, and Gram-negative pathogens was highly associated with polymicrobial PJI. Of the 19 polymicrobial PJIs, only 2 patients occurred infection recurrence, which is similar with the result of 6 of 107 patients in the monomicrobial PJI (P = .225). The Harris Hip Score of the polymicrobial group showed no difference from that of the monomicrobial group (78 vs 80; P = .181). Nevertheless, the polymicrobial group exhibited inferior Hospital for Special Surgery knee score relative to the monomicrobial group (77 vs 79; P = .017).ConclusionWith rational and targeted use of antibiotics, single-stage revision can effectively control polymicrobial infections, and achieve favorable outcomes similar to that in monomicrobial patients. However, this regimen is still needed to be further confirmed, especially in the infections with different microbial species simultaneously. Additionally, obese patients with a sinus tract and those who had prior revisions had a greater risk of polymicrobial PJI.     

Feasibility of Induction Chemotherapy Using Bronchial Arterial Infusion for Locally Advanced Non-Small Cell Lung Cancer: A Pilot Study

Purpose: We examined the feasibility and effectiveness of bronchial arterial infusion (BAI) as induction chemotherapy before surgery for locally advanced non-small cell lung cancer (NSCLC). Methods: Eighteen patients with locally advanced NSCLC were given BAI consisting of cis-diamminedichloroplatinum (CDDP) (50–100 mg/m²) as induction chemotherapy before surgery (induction BAI). Six patients with clinical stage IIIA cancer had bulky N2 metastatic lymph nodes, and 12 patients with clinical stage IIIB cancer had T4 disease. Results: Of the 18 patients, 12 (67%) showed a partial response to the BAI therapy. Standard pulmonary resection was performed in 5 patients, pulmonary resection with the combined resection of adjacent organs was performed in 10 patients, and pulmonary resection with carinal resection and reconstruction was performed in 3 patients. Complete resection was possible in 14 patients (78%). There were no serious BAI therapy-related complications or postoperative deaths. The 5-year survival rate of the 18 patients was 35.7% and the median survival time (MST) was 19.4 months. Survival was better when complete resection was achieved after the induction BAI, especially in patients with stage IIIB (T4) disease. Conclusion: Based on our preliminary findings, BAI with CDDP as induction chemotherapy is feasible and may be an effective therapeutic modality for locally advanced NSCLC. Received: July 26, 2001 / Accepted: March 5, 2002